Responses
Section 4: Clinical pharmacy services
4CPS-193 Effectiveness and safety of intravenous ustekinumab intensification in Crohn’s disease with loss of response or partial response to subcutaneous therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.